Effect of improvement in lower urinary tract symptoms on sexual function in men

Tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin

Kyungtae Ko, Dae Yul Yang, Won Ki Lee, Sae Woong Kim, Du Geon Moon, Ki Hak Moon, Nam Cheol Park, Jong Kwan Park, Hwan Cheol Son, Sung Won Lee, Jae Seog Hyun, Kwangsung Park

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To evaluate how much the improvement of lower urinary tract symptoms (LUTS) affects sexual function and which storage symptoms or voiding symptoms have the greatest effect on sexual function. Materials and Methods: A total of 187 patients were enrolled in this study. Patients were randomly assigned to receive either tamsulosin 0.2 mg (group A) or tamsulosin 0.2 mg and solifenacin 5 mg (group B). At 4 weeks and 12 weeks, the LUTS and sexual function of the patients were evaluated by use of the International Index of Erectile Function-5 (IIEF5), International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS) questionnaire, uroflowmetry, and bladder scan. Results: Both groups A and B showed statistically significant improvements in IPSS, OABSS, and quality of life (QoL). Group A showed improved maximum flow rate, mean flow rate, and residual urine volume by time. Group B did not show an improvement in flow rate or residual urine volume but total voiding volume increased with time. The IIEF5 score was not improved in either group. In group A, the IIEF5 score dropped from 13.66±4.97 to 11.93±6.14 after 12 weeks (p=0.072). Group B showed a decline in the IIEF5 score from 13.19±5.91 to 12.45±6.38 (p=0.299). Although group B showed a relatively smaller decrease in the IIEF5 score, the difference between the two groups was not significant (p=0.696). Conclusions: Tamsulosin monotherapy and combination therapy with solifenacin did not improve erectile function despite improvements in voiding symptoms and QoL. The improvement in storage symptoms did not affect erectile function.

Original languageEnglish
JournalKorean Journal of Urology
Volume55
Issue number9
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

tamsulosin
Lower Urinary Tract Symptoms
Overactive Urinary Bladder
Residual Volume
Prostate
Quality of Life
Urine
Urinary Bladder
Therapeutics
Solifenacin Succinate

Keywords

  • Erectile dysfunction
  • Lower urinary tract symptoms
  • Overactive urinary Bladder

ASJC Scopus subject areas

  • Urology

Cite this

Effect of improvement in lower urinary tract symptoms on sexual function in men : Tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. / Ko, Kyungtae; Yang, Dae Yul; Lee, Won Ki; Kim, Sae Woong; Moon, Du Geon; Moon, Ki Hak; Park, Nam Cheol; Park, Jong Kwan; Son, Hwan Cheol; Lee, Sung Won; Hyun, Jae Seog; Park, Kwangsung.

In: Korean Journal of Urology, Vol. 55, No. 9, 01.01.2014.

Research output: Contribution to journalArticle

Ko, Kyungtae ; Yang, Dae Yul ; Lee, Won Ki ; Kim, Sae Woong ; Moon, Du Geon ; Moon, Ki Hak ; Park, Nam Cheol ; Park, Jong Kwan ; Son, Hwan Cheol ; Lee, Sung Won ; Hyun, Jae Seog ; Park, Kwangsung. / Effect of improvement in lower urinary tract symptoms on sexual function in men : Tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. In: Korean Journal of Urology. 2014 ; Vol. 55, No. 9.
@article{a0b11adee9d242bda132bda434b49087,
title = "Effect of improvement in lower urinary tract symptoms on sexual function in men: Tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin",
abstract = "Purpose: To evaluate how much the improvement of lower urinary tract symptoms (LUTS) affects sexual function and which storage symptoms or voiding symptoms have the greatest effect on sexual function. Materials and Methods: A total of 187 patients were enrolled in this study. Patients were randomly assigned to receive either tamsulosin 0.2 mg (group A) or tamsulosin 0.2 mg and solifenacin 5 mg (group B). At 4 weeks and 12 weeks, the LUTS and sexual function of the patients were evaluated by use of the International Index of Erectile Function-5 (IIEF5), International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS) questionnaire, uroflowmetry, and bladder scan. Results: Both groups A and B showed statistically significant improvements in IPSS, OABSS, and quality of life (QoL). Group A showed improved maximum flow rate, mean flow rate, and residual urine volume by time. Group B did not show an improvement in flow rate or residual urine volume but total voiding volume increased with time. The IIEF5 score was not improved in either group. In group A, the IIEF5 score dropped from 13.66±4.97 to 11.93±6.14 after 12 weeks (p=0.072). Group B showed a decline in the IIEF5 score from 13.19±5.91 to 12.45±6.38 (p=0.299). Although group B showed a relatively smaller decrease in the IIEF5 score, the difference between the two groups was not significant (p=0.696). Conclusions: Tamsulosin monotherapy and combination therapy with solifenacin did not improve erectile function despite improvements in voiding symptoms and QoL. The improvement in storage symptoms did not affect erectile function.",
keywords = "Erectile dysfunction, Lower urinary tract symptoms, Overactive urinary Bladder",
author = "Kyungtae Ko and Yang, {Dae Yul} and Lee, {Won Ki} and Kim, {Sae Woong} and Moon, {Du Geon} and Moon, {Ki Hak} and Park, {Nam Cheol} and Park, {Jong Kwan} and Son, {Hwan Cheol} and Lee, {Sung Won} and Hyun, {Jae Seog} and Kwangsung Park",
year = "2014",
month = "1",
day = "1",
doi = "10.4111/kju.2014.55.9.608",
language = "English",
volume = "55",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "9",

}

TY - JOUR

T1 - Effect of improvement in lower urinary tract symptoms on sexual function in men

T2 - Tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin

AU - Ko, Kyungtae

AU - Yang, Dae Yul

AU - Lee, Won Ki

AU - Kim, Sae Woong

AU - Moon, Du Geon

AU - Moon, Ki Hak

AU - Park, Nam Cheol

AU - Park, Jong Kwan

AU - Son, Hwan Cheol

AU - Lee, Sung Won

AU - Hyun, Jae Seog

AU - Park, Kwangsung

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To evaluate how much the improvement of lower urinary tract symptoms (LUTS) affects sexual function and which storage symptoms or voiding symptoms have the greatest effect on sexual function. Materials and Methods: A total of 187 patients were enrolled in this study. Patients were randomly assigned to receive either tamsulosin 0.2 mg (group A) or tamsulosin 0.2 mg and solifenacin 5 mg (group B). At 4 weeks and 12 weeks, the LUTS and sexual function of the patients were evaluated by use of the International Index of Erectile Function-5 (IIEF5), International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS) questionnaire, uroflowmetry, and bladder scan. Results: Both groups A and B showed statistically significant improvements in IPSS, OABSS, and quality of life (QoL). Group A showed improved maximum flow rate, mean flow rate, and residual urine volume by time. Group B did not show an improvement in flow rate or residual urine volume but total voiding volume increased with time. The IIEF5 score was not improved in either group. In group A, the IIEF5 score dropped from 13.66±4.97 to 11.93±6.14 after 12 weeks (p=0.072). Group B showed a decline in the IIEF5 score from 13.19±5.91 to 12.45±6.38 (p=0.299). Although group B showed a relatively smaller decrease in the IIEF5 score, the difference between the two groups was not significant (p=0.696). Conclusions: Tamsulosin monotherapy and combination therapy with solifenacin did not improve erectile function despite improvements in voiding symptoms and QoL. The improvement in storage symptoms did not affect erectile function.

AB - Purpose: To evaluate how much the improvement of lower urinary tract symptoms (LUTS) affects sexual function and which storage symptoms or voiding symptoms have the greatest effect on sexual function. Materials and Methods: A total of 187 patients were enrolled in this study. Patients were randomly assigned to receive either tamsulosin 0.2 mg (group A) or tamsulosin 0.2 mg and solifenacin 5 mg (group B). At 4 weeks and 12 weeks, the LUTS and sexual function of the patients were evaluated by use of the International Index of Erectile Function-5 (IIEF5), International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS) questionnaire, uroflowmetry, and bladder scan. Results: Both groups A and B showed statistically significant improvements in IPSS, OABSS, and quality of life (QoL). Group A showed improved maximum flow rate, mean flow rate, and residual urine volume by time. Group B did not show an improvement in flow rate or residual urine volume but total voiding volume increased with time. The IIEF5 score was not improved in either group. In group A, the IIEF5 score dropped from 13.66±4.97 to 11.93±6.14 after 12 weeks (p=0.072). Group B showed a decline in the IIEF5 score from 13.19±5.91 to 12.45±6.38 (p=0.299). Although group B showed a relatively smaller decrease in the IIEF5 score, the difference between the two groups was not significant (p=0.696). Conclusions: Tamsulosin monotherapy and combination therapy with solifenacin did not improve erectile function despite improvements in voiding symptoms and QoL. The improvement in storage symptoms did not affect erectile function.

KW - Erectile dysfunction

KW - Lower urinary tract symptoms

KW - Overactive urinary Bladder

UR - http://www.scopus.com/inward/record.url?scp=84907153263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907153263&partnerID=8YFLogxK

U2 - 10.4111/kju.2014.55.9.608

DO - 10.4111/kju.2014.55.9.608

M3 - Article

VL - 55

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 9

ER -